Provided by Tiger Trade Technology Pte. Ltd.

Merck

105.66
+5.265.24%
Volume:22.23M
Turnover:2.32B
Market Cap:262.25B
PE:13.98
High:105.84
Open:100.73
Low:100.71
Close:100.40
52wk High:105.84
52wk Low:73.31
Shares:2.48B
Float Shares:2.48B
Volume Ratio:1.04
T/O Rate:0.90%
Dividend:3.24
Dividend Rate:3.07%
EPS(TTM):7.56
EPS(LYR):6.76
ROE:39.49%
ROA:13.76%
PB:5.06
PE(LYR):15.63

Loading ...

Weekly Winners | Regeneron Surges 9%; Alphabet and Ross Stores Jump 8%; Medtronic Gains 6%

Tiger Newspress
·
Nov 23

This Medicare premium just crossed $200 for the first time. Here's why.

Dow Jones
·
Nov 22

Bristol Myers Squibb Stock Is Too Cheap to Ignore -- Barrons.com

Dow Jones
·
Nov 22

Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer

THOMSON REUTERS
·
Nov 22

BRIEF-FDA Approves KEYTRUDA® (pembrolizumab) And KEYTRUDA QLEX™ (Pembrolizumab And Berahyaluronidase Alfa-Pmph), Each With Padcev® (enfortumab vedotin-ejfv)

Reuters
·
Nov 22

Merck: FDA approves Keytruda, Keytruda Qlex in combo with Padcev

TIPRANKS
·
Nov 22

FDA Approves Keytruda® (Pembrolizumab) and Keytruda Qlex™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph), Each With Padcev® (Enfortumab Vedotin-Ejfv), as Perioperative Treatment for Adults With Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

THOMSON REUTERS
·
Nov 22

BRIEF-FDA Approves Pembrolizumab With Enfortumab Vedotin-Ejfv For Muscle Invasive Bladder Cancer

Reuters
·
Nov 22

Is Merck Attractively Priced After Pipeline Success Drives 8.4% Rally?

Simply Wall St.
·
Nov 22

FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer

Dow Jones
·
Nov 22

Merck Shares up 5.3% After FDA Approves Combination Treatment for Muscle Invasive Bladder Cancer

THOMSON REUTERS
·
Nov 22

Stock Track | Merck Soars 5% on FDA Approval for Bladder Cancer Drug Combination

Stock Track
·
Nov 22

Dow Up Nearly 300 Points On Gains In Sherwin-Williams Co., Merck Shares

Dow Jones
·
Nov 21

Lilly becomes first drugmaker to join trillion-dollar club on weight-loss demand boom

Reuters
·
Nov 21

Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A

LiveWire
·
Nov 21

BRIEF-VIPC Signs MoU With Astrazeneca, Eli Lilly, Merck

Reuters
·
Nov 21

Vipc: Partnership Commits $120 Mln of Workforce Investment From AstraZeneca, Lilly, and Merck

THOMSON REUTERS
·
Nov 21

This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy. -- Barrons.com

Dow Jones
·
Nov 20

Equinix and Lenovo Launch High-Performance Supercomputer for Merck KGaA

Reuters
·
Nov 20

Merck Finalizes WINREVAIR Negotiations with pan-Canadian Pharmaceutical Alliance

Reuters
·
Nov 20